trending Market Intelligence /marketintelligence/en/news-insights/trending/FM4pg3DyhRoGQVI_3ure4w2 content esgSubNav
In This List

Venn Life Sciences unit goes public

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Venn Life Sciences unit goes public

Venn Life Sciences Holdings PLC unit Integumen PLC went public on the AIM market of the London Stock Exchange, raising £2.3 million in an equity placement.

Venn Life owned 41.51% of the Ireland-based personal healthcare company and now owns 25.59% of the unit following admission to the market.

Venn Life is participating in the IPO and subscribed for 8 million new shares of Integumen for a total cash consideration of £400,000. Based on the placing price of 5 pence per share, Integumen has a market capitalization of about £8.3 million.

As part of the IPO, Paul Kennedy has retired from the Venn board and become a director of Integumen.